The genetics of hyperuricaemia and gout
In this update on the genetics of hyperuricaemia and gout, the authors describe the associations between common genetic variants, serum uric acid levels and gout as well as the role of these genetic variants in gout pathogenesis. Pharmacogenetic associations between HLA-B * 5801 and severe allopurin...
Saved in:
Published in | Nature reviews. Rheumatology Vol. 8; no. 10; pp. 610 - 621 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.10.2012
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In this update on the genetics of hyperuricaemia and gout, the authors describe the associations between common genetic variants, serum uric acid levels and gout as well as the role of these genetic variants in gout pathogenesis. Pharmacogenetic associations between
HLA-B
*
5801
and severe allopurinol-hypersensitivity reactions and the potential causal role of urate in cardiovascular disease are also discussed.
Gout is a common and very painful inflammatory arthritis caused by hyperuricaemia. This Review provides an update on the genetics of hyperuricaemia and gout, including findings from genome-wide association studies. Most of the genes that associated with serum uric acid levels or gout are involved in the renal urate-transport system. For example, the urate transporter genes
SLC2A9
,
ABCG2
and
SLC22A12
modulate serum uric acid levels and gout risk. The net balance between renal urate absorption and secretion is a major determinant of serum uric acid concentration and loss-of-function mutations in
SLC2A9
and
SLC22A12
cause hereditary hypouricaemia due to reduced urate absorption and unopposed urate secretion. However, the variance in serum uric acid explained by genetic variants is small and their clinical utility for gout risk prediction seems limited because serum uric acid levels effectively predict gout risk. Urate-associated genes and genetically determined serum uric acid levels were largely unassociated with cardiovascular–metabolic outcomes, challenging the hypothesis of a causal role of serum uric acid in the development of cardiovascular disease. Strong pharmacogenetic associations between
HLA-B
*
5801
alleles and severe allopurinol-hypersensitivity reactions were shown in Asian and European populations. Genetic testing for
HLA-B
*
5801
alleles could be used to predict these potentially fatal adverse effects.
Key Points
The majority of the genes that associate with hyperuricaemia and gout in genome-wide association studies have been implicated in the renal urate-transport system
Genetic variation explains only a modest level of variance in serum uric acid levels (∼6%)
Serum uric acid levels are determined by the net balance between urate absorption and secretion, which is mediated by separate sets of transporters in the renal proximal tubule
The clinical utility of testing for urate-associated genes seems limited because serum urate levels themselves can effectively predict gout risk at a low cost
Urate-associated genes and genetically determined urate levels have been largely unassociated with cardiovascular or metabolic outcomes, suggesting that serum uric acid does not have a causal role in these outcomes
Strong pharmacogenetic associations between
HLA-B
*
5801
alleles and severe allopurinol-hypersensitivity reactions have been shown in Asian and European populations, suggesting clinical utility of testing for these alleles |
---|---|
ISSN: | 1759-4790 1759-4804 |
DOI: | 10.1038/nrrheum.2012.144 |